CD274 and non-small cell lung carcinoma: In the phase II POPLAR study, previously treated NSCLC patients (in a second- or third-line setting) were stratified by PD-L1 expression on tumor-infiltrating immune cells (ICs) and TCs assessed by IHC with the SP142 antibody and were randomized to receive atezolizumab or docetaxel treatment.